Difference between revisions of "Team:TCU Taiwan/Modeling/Protein structure"

Revision as of 02:17, 8 September 2015

About our modeling

為了能夠使我們更有效地拿到我們的指定抗菌肽，我們在設計序列時在AMPs的N-terminal加上了來自S.lividans幾丁質酶C的signal peptide (附上氨基酸序列)。這個pre-mature peptide在經過periplasmic space時會被peptidase辨認並且做切割。Peptidase會辨認signal peptide 上Ala-Gln-Ala序列，並且從signal和mature peptide中間的兩個Ala間將之分開。為了使peptidase能夠順利辨認並且切割，我們在AMP的N-terminal多加了一個Ala氨基酸，以確保整個系統能順利運作。我們利用模擬技術，利用原本的已知結構，去推測在我們多加了一個Ala的情況下，是否會影響AMPs的蛋白結構折疊。

In order to have more efficient to get our AMPs, we treated signal peptide upstream of the N-terminal of mature antimicrobial peptides. This signal peptide is comes from chitinase C of S.lividans (MGFRHKAAALAATLALPLAGLVGLASPAQA). When the pre-mature peptides go through the periplasmic space, peptidase will identified the cleavage site Ala-Gln-Ala and cut at the double Ala between the signal and mature peptide.

To make sure the secretion system is work we attach an Ala at the N-terminal of AMPs. We used protein secondary structure prediction software base on the known peptide structure to analysis whether the attached Ala affect the peptide folding process or not.

Signiferin

with Ala attach
N-terminal

Signiferin

without Ala attach
N-terminal
Result 2

The first column shows the amino acid sequence we predict. The second column shows that AMPs corresponding secondary structure state are still a-helix. The third column shows the probability of correct prediction.

Signiferin以及Epinicidin-1都是由 a helix結構所構成，在我們的模擬分析後，不管是signiferin還是Epinecidin-1在N-terminal多加了一個Ala後並不影響蛋白的摺疊結構。

Through the secondary structure predicted. The result shows whatever Signiferin or Epinecidin-1 the attached of Ala didn’t affect peptide-folding process. They are still a-helix structure.

Conclusion

Contact us
tcutaiwan@gmail.com
No.701, Sec. 3, Zhongyang Rd. Hualien 97004, Taiwan

@@ Line 60: / Line 60: @@
 <table width="95%"  align="center">
    <tr>
-     <td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> Signiferin</br></font></span><img src="https://static.igem.org/mediawiki/2015/1/17/2015tcutaiwanmodelingsigaddA.JPG" align=center width="72%"  title="with amino acid A"></td>
+     <td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> Signiferin</br></font></span><img src="https://static.igem.org/mediawiki/2015/1/17/2015tcutaiwanmodelingsigaddA.JPG" align=center width="80%"  title="with amino acid A"></td>
      <td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> with Ala attach </br>N-terminal</br></font></span><img src="https://static.igem.org/mediawiki/2015/2/2a/2015tcutaiwanmodelingdataSigaddA.JPG" align=center width="72%"  title="Result 1"></td>
    </tr>
@@ Line 71: / Line 71: @@
 <table width="95%"  align="center">
    <tr>
-  <td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> Signiferin</br></font></span><img src="https://static.igem.org/mediawiki/2015/6/67/2015tcutaiwanmodelingsigwithoutA.JPG" align=center width="72%"  title="without amino acid A"></td>
+  <td width="45%" align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> Signiferin</br></font></span><img src="https://static.igem.org/mediawiki/2015/6/67/2015tcutaiwanmodelingsigwithoutA.JPG" align=center width="80%"  title="without amino acid A"></td>
      <td width="45%"  align="center"><span style="font-family:Arial Black;"><font size="7"><font-weight: 800;> without Ala attach </br>N-terminal</br><img src="https://static.igem.org/mediawiki/2015/1/12/2015tcutaiwanmodelingdataSigwithoutA.JPG" align=center width="72%"  title="Result 2"></font></span></td>
    </tr>  </table>